Remove news target-reports-november-sales
article thumbnail

COVID-19 ventilator demand fuels Philips Q3 sales

pharmaphorum

Huge demand for ventilators and patient monitors spurred third quarter sales for Royal Philips, the company announced. The Dutch health technology group reported sales of €4.98bn, a 10% year-over-year growth. Sales were down 3%, to €1.97bn compared to a 9% dip in Q2.

Hospitals 103
article thumbnail

Amgen agrees $26bn for Horizon following Sanofi withdrawal

pharmaphorum

In a fresh update, Bloomberg has reported that US biotech Amgen Inc. billion ($3.6bn) in annual sales from Tepezza (teprotumumab), a treatment for the painful autoimmune condition thyroid eye disease (TED). J&J soon pulled out, but the news resulted also in an increased market value of €20.9 Under Rule 8.3(a)

103
103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Changing Faces: biopharma hires from November 2022

pharmaphorum

The month of November saw a number of notable hires and personnel moves in biotech and pharma. Boehringer Ingelheim taps new head of medicine. As we reported 4th November, Boehringer Ingelheim brought on former Novartis neurosciences head Lykke Hinsch Gylvin (pictured below) into the role of head of medicine and chief medical officer.

article thumbnail

WHO urges supply chain to take action on contaminated medicines

European Pharmaceutical Review

Ensure that all medical products in their respective markets are approved for sale by competent authorities and obtainable from authorised/licensed suppliers in the supply chain. Increase market surveillance including risk-based targeted testing for medical products released in their respective markets including informal markets.

91
article thumbnail

Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab

pharmaphorum

Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab as the first-ever disease-modifying treatment for Alzheimer’s disease. Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s.

FDA 89
article thumbnail

20 Key Christmas Marketing Dates for eCommerce Businesses in 2022 #76

The Social Pharmacist

Every holiday represents an opportunity to drive sales and increase revenue. From Thanksgiving, Christmas to New Year’s Day, the spirit of celebrations and gift-giving boosts the sales for all online and physical stores. Christmas Marketing doesn’t mean direct sales. Notably, Cyber week kicks off Christmas sales.

article thumbnail

20 Key Christmas Marketing Dates for eCommerce Businesses in 2022 #76

The Social Pharmacist

Every holiday represents an opportunity to drive sales and increase revenue. From Thanksgiving, Christmas to New Year’s Day, the spirit of celebrations and gift-giving boosts the sales for all online and physical stores. Christmas Marketing doesn’t mean direct sales. Notably, Cyber week kicks off Christmas sales.